Prostate News Archive
18-Feb-2007
Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally ... (RedNova)
By Steuber, Thomas; Vickers, Andrew J; Serio, Angel M; Vaisanen, Ville; Et al Background: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) and prostate-specific antigen (PSA) with prostate cancers of unfavorable prognosis. Spectrum requests approval of prostate cancer therapy (Pharmaceutical Business Review)
Spectrum Pharmaceuticals has filed its new drug application to US regulators for satraplatin, its drug candidate for the treatment of hormone refractory prostate cancer for those who have failed chemotherapy. New Study Shows Cough Medicine Effective Against Prostate Cancer (Medical News Today)
A presentation made at the 17th International Prostate Cancer Update Conference in Vail, Colorado, has shown noscapine to be effective against prostate cancer.Noscapine, a non-addictive derivative of opium, has been used worldwide since the 1950's as an anti-cough medication. Noscapine was originally proposed as an anti-cancer agent in the early 1960's. [click link for full article] Preclinical Efficacy Data On Medivation's MDV3100 To Be Presented At ASCO-sponsored Prostate Cancer Symposium (Medical News Today)
Medivation, Inc. (Amex: MDV) today announced that preclinical efficacy data on MDV3100, a novel small molecule the Company is developing to treat hormone-refractory prostate cancer, will be presented later this month at the Prostate Cancer Symposium, a gathering sponsored by the American Society of Clinical Oncology. Charles Sawyers, M.D. [click link for full article] Spectrum Pharmaceuticals Announces Completion Of NDA Filing For Satraplatin For Hormone Refractory Prostate Cancer (Medical News Today)
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced the completion of the submission of the New Drug Application (NDA) to the US Food & Drug Administration (FDA) for satraplatin, the Company's lead drug candidate for the treatment of hormone refractory prostate cancer (HRPC) for those patients who have failed prior chemotherapy. [click link for full article]
Back to Prostate News Archive
